Mind Medicine (MindMed) Inc
MNMD9.360USD
+0.920+10.90%
收盘 08/04, 16:00（美东）报价延迟15分钟
709.52M总市值
亏损市盈率 TTM
关于 Mind Medicine (MindMed) Inc 公司
Mind Medicine (MindMed) Inc. 是一家临床阶段的生物制药公司，致力于开发治疗脑部健康障碍的产品。该公司正在开发一系列具有和不具有急性感知效应的候选产品，以神经递质通路为目标。这具体包括源自迷幻药和共情剂类药物的经过药物优化的候选产品，包括该公司的候选产品 MM-120 和 MM-402。MM120 是一种专有的、经过药物优化的酒石酸麦角酸单抗，该公司正在开发这种药物用于治疗广泛性焦虑症 (GAD)。MM-120 还正在研究一种亚感知重复给药方案，用于治疗注意力缺陷多动障碍 (ADHD)。 MM-402，也称为 R(-)-MDMA，是该公司的 3,4-亚甲基二氧基甲基苯丙胺 (MDMA) 的 R 对映体形式，该公司正在开发该形式用于治疗自闭症谱系障碍 (ASD)。
公司简介
公司代码MNMD
公司名称Mind Medicine (MindMed) Inc
上市日期May 04, 2015
CEOMr. Robert (Rob) Barrow
员工数量74
证券类型Ordinary Share
年结日May 04
公司地址One World Trade Center
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10007
电话12122206633
网址
公司代码MNMD
上市日期May 04, 2015
CEOMr. Robert (Rob) Barrow
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
250.05K
-9.58%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
42.63K
-21.23%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Brandi L. Roberts
Ms. Brandi L. Roberts
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
250.05K
-9.58%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
42.63K
-21.23%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Brandi L. Roberts
Ms. Brandi L. Roberts
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.84%
Commodore Capital LP
5.95%
Blackstone Alternative Asset Management, L.P.
4.71%
Driehaus Capital Management, LLC
4.40%
Octagon Capital Advisors LP
3.97%
Other
74.13%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.84%
Commodore Capital LP
5.95%
Blackstone Alternative Asset Management, L.P.
4.71%
Driehaus Capital Management, LLC
4.40%
Octagon Capital Advisors LP
3.97%
Other
74.13%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
21.93%
Hedge Fund
17.33%
Investment Advisor
13.50%
Research Firm
1.70%
Individual Investor
1.09%
Bank and Trust
0.28%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Other
43.76%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
378
42.50M
56.25%
-6.01M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
2023Q1
386
7.15M
19.19%
-755.92K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
5.20M
6.88%
-370.12K
-6.64%
Mar 31, 2025
Commodore Capital LP
4.53M
5.99%
+216.57K
+5.03%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.75%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
3.35M
4.44%
-24.80K
-0.73%
Mar 31, 2025
Octagon Capital Advisors LP
3.02M
3.99%
--
--
Mar 31, 2025
Marshall Wace LLP
2.59M
3.43%
+91.77K
+3.67%
Mar 31, 2025
Deep Track Capital LP
2.50M
3.31%
-316.59K
-11.24%
Mar 31, 2025
State Street Global Advisors (US)
1.84M
2.44%
+60.72K
+3.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.75M
2.32%
-144.28K
-7.60%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.67M
2.21%
-56.30K
-3.27%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
AdvisorShares Psychedelics ETF
8.73%
SPDR S&P Pharmaceuticals ETF
0.85%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.6%
iShares U.S. Pharmaceuticals ETF
0.22%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Nuveen ESG Small-Cap ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
查看更多
AdvisorShares Psychedelics ETF
占比8.73%
SPDR S&P Pharmaceuticals ETF
占比0.85%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.6%
iShares U.S. Pharmaceuticals ETF
占比0.22%
iShares Micro-Cap ETF
占比0.11%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.05%
Nuveen ESG Small-Cap ETF
占比0.04%
iShares Russell 2000 Value ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
公告日期
类型
比率
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
Aug 23, 2022
Merger
15<1
